ArticleCancer medicine2023
Gastroesophageal reflux disease and risk of cancer: Findings from the Korean National Health Screening Cohort.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Pooled it
- GERD and Upper Aerodigestive Tract Cancer Risk: A Systematic Review and Meta-Analysis.The Laryngoscope · 2026Pooled it
- Association of gastroesophageal reflux disease with the incidence of multiple cancers: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Relationship between gastroesophageal reflux and chronic kidney disease: A meta-analysis of 4 million patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Pooled it
- The Association Between Gastroesophageal Reflux Disease and Lung Cancer: A Systematic Review and Meta Analysis.Journal of clinical medicine · 2026Review
- The ratio of omega-6 fatty acids to omega-3 fatty acids mediating the effect of gastroesophageal reflux disease on pancreatic cancer risk: a two-step mediation Mendelian randomisation study.BMC gastroenterology · 2025Article
- Impact of referral delays on dysphagia outcomes in a Saudi tertiary center.World journal of gastrointestinal endoscopy · 2025Article
- Association Between Gastroesophageal Reflux Disease and Extraesophageal Malignancies: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Deciphering the dual role of autophagy in gastric cancer and gastroesophageal junction cancer: from tumor suppression to cancer progression.Discover oncology · 2025Review
- Exploring the genetic link between gastroesophageal reflux disease and pancreatic cancer: insights from Mendelian randomization.BMC cancer · 2025Article
- Histomorphological development and progression of gastric intramucosal papillary adenocarcinoma-a retrospective study.Frontiers in oncology · 2025Article
- Early onset gastric cancer: clinical and molecular insights into a rising epidemic among younger adults.Proceedings (Baylor University. Medical Center) · 2025Article
- Association Between Gastroesophageal Reflux Disease and Periodontitis: A Longitudinal Follow-Up Study from the Korean National Health Screening Cohort.Biomedicines · 2024Article
- Gastroesophageal reflux disease and risk of cancer: Findings from the Korean National Health Screening Cohort.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
aimLittle is known about the association of cancers other than esophageal adenocarcinoma with gastroesophageal reflux disease (GERD). This study aimed to examine the association between GERD and the risk of different types of cancer.
methodsA cohort study was conducted using data from the National Health Screening Cohort. We included 10,261 GERD patients and 30,783 non-GERD individuals who were matched in a 1:3 ratio by age and sex. All participants were followed-up until cancer diagnosis, death, or end of the study (December 31, 2015). Hazard ratios were calculated using the Cox proportional hazards model, adjusting for smoking and alcohol consumption, physical activity, body mass index, income, area, and Charlson Comorbidity Index.
resultsThe median follow-up time was 9.9 years. GERD was associated with an increased risk of esophageal (adjusted hazard ratios [aHR] = 3.20 [1.89-5.41]), laryngeal (aHR = 5.42 [2.68-10.96]), and thyroid cancers (aHR = 1.91 [1.55-2.34]) after controlling for all covariates. The results were consistent when examining GERD with esophagitis (K210) and without esophagitis (K219) separately. For thyroid cancer, the results were insignificant after controlling for having ever-received thyroid biopsy procedures. A dose-response relationship was found between GERD and esophageal cancer as well as laryngeal cancer, with patients with a longer duration of GERD treatment showing a stronger effect. In contrast, GERD was associated with a reduced risk of colorectal (aHR = 0.73 [0.59-0.90]), liver (aHR = 0.67 [0.51-0.89]), and pancreatic cancers (aHR = 0.43 [0.24-0.76]), which might have resulted from differences in healthcare utilization between GERD and non-GERD groups.
conclusionGERD was associated with an increased risk of esophageal and laryngeal cancers. Additionally, early detection and treatment of precancerous lesions among the GERD group could lead to a lower risk of colorectal, liver, and pancreatic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.